Navigation Links
Asmacure to Present Four Posters on Novel Pulmonary Development Compound ASM-024 at American Thoracic Society 2013 International Conference
Date:5/16/2013

ter session B32 – Advances in Asthma Therapy (Halls C-D)
8:15 a.m. – 4:30 p.m.
  • Relaxant Effects Of ASM-024, A New Compound With Dual Nicotinic And Muscarinic Activity, On b 2-Agonist Desensitized Guinea-Pig Tracheas (Poster #B41)
    Lead author: Yvon Cormier , M.D., Asmacure and Universite Laval
    Poster session B32 – Advances in Asthma Therapy (Halls C-D)
    8:15 a.m.-4:30 p.m.

About Asthma
Asthma is a reversible obstructive lung disease, caused by increased reaction of the airways to various stimuli. It is a chronic inflammatory condition with acute exacerbations. Asthma can be a life-threatening disease if not properly managed. According to the American Lung Association in 2011 it was estimated that 25.9 million Americans currently have asthma, including 7.1 million children under 18. Of these, 13.2 million Americans (4.1 million children) had an asthma attack. Close to 2.1 million emergency room visits were attributed to asthma in 2009.

About ASM-024
The company's lead development compound, ASM-024, with its novel mechanism of action, has demonstrated the capabilities of inhibitory effects on inflammation, bronchoprotection and smooth muscle relaxation in pre-clinical asthma models. ASM-024 delivered as a solution for nebulization achieved proof of concept in the treatment of patients with asthma in a phase 2 clinical trial program. The company is now focused on bridging from the ASM-024 solution formulation to the development of the compound in a dry powder for inhalation (DPI) dosage form. Typically, DPI's are a preferred dosage form for pulmonary products by allowing for delivery of lower, more optimal dosing with greater lung deposition.

ASM-024 demonstrated a highly-significant effect on FEV₁ and methacholine PC₂₀ pre-allergen challenge in a phase 2 study utilizing the solution for nebulizat
'/>"/>

SOURCE Asmacure
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Asmacure Dosed First Subjects With ASM-024 Dry Powder For Inhalation
2. AbbVie to Present Data on Investigational Anti-Cancer Compounds at American Society of Clinical Oncology Annual Meeting
3. Amgen Highlights Data To Be Presented At American Society of Clinical Oncology Annual Meeting
4. Boehringer Ingelheim Presents Progression-Free Survival Data for Investigational Afatinib and Nintedanib in Advanced NSCLC
5. ASCO 2013: Boehringer Ingelheim to Present Data Across Multiple Cancers, Including Different Treatment Settings for Advanced NSCLC
6. Arno Therapeutics to Present Positive, New Data Supporting the Potential of Onapristone in Endometrial and Breast Cancers at ASCO 2013 Annual Meeting
7. Bayer to Present New Data Across Oncology Portfolio at ASCO 2013
8. Cumberland Pharmaceuticals To Present At The UBS Global Healthcare Conference In New York
9. Cardium Presents First Quarter 2013 Financial Results And Reports On Recent Developments
10. AMRI CFO to Present at the UBS Global Healthcare Conference
11. Array BioPharma Announces Clinical Data Presentations At The 2013 ASCO Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)...  According to their CEO, Rob Bohacs ... is going through a complete transformation with highly ... the current clinical trial management process isn,t configured ... trials, which will ultimately drive the prescription cancer ... has been recognized by the National Cancer Institute as ...
(Date:9/30/2014)... 2014   Easy Breathe , the fastest growing ... that it now offers the revolutionary AirSense ... first sleep apnea therapy devices with internal cellular modems.  ... track and share real-time data on each user,s quality ... therapy.  In addition, the internal modem allows the CPAP ...
(Date:9/30/2014)... , Sept. 30, 2014 Valeant Pharmaceuticals International, ... today announced that the company,s Bridgewater, New ... the U.S. Food and Drug Administration (FDA) relating to ... with regards to Sculptra Aesthetic injectable, which was divested ... to the management of Valeant,s contract manufacturers (rather than ...
Breaking Medicine Technology:Small Denver Company Pharmatech driving a large revolution in how cancer clinical trials are managed 2Easy Breathe Now Offers World's First "Smart" CPAP Device to Treat Sleep Apnea 2Easy Breathe Now Offers World's First "Smart" CPAP Device to Treat Sleep Apnea 3Easy Breathe Now Offers World's First "Smart" CPAP Device to Treat Sleep Apnea 4Valeant Pharmaceuticals' Bridgewater Location Receives Warning Letter From FDA 2
... Today Brainlab announced the 500th sale of its ... The scale of uptake highlights physicians continued focus on ... their ongoing investment in ensuring access to advanced radiation ... system, first developed almost a decade ago, has been ...
... 16, 2012 On January 9, 2012, Questcor ... from an individual representing herself to be associated ... individual requested that the Company provide responses to ... January 10, 2012.  Due to management,s schedule, the ...
Cached Medicine Technology:Brainlab ExacTrac® System Achieves Major Sales Milestone 2Questcor Pharmaceuticals Responds to Questions From Investor Blog 2Questcor Pharmaceuticals Responds to Questions From Investor Blog 3Questcor Pharmaceuticals Responds to Questions From Investor Blog 4Questcor Pharmaceuticals Responds to Questions From Investor Blog 5Questcor Pharmaceuticals Responds to Questions From Investor Blog 6Questcor Pharmaceuticals Responds to Questions From Investor Blog 7Questcor Pharmaceuticals Responds to Questions From Investor Blog 8Questcor Pharmaceuticals Responds to Questions From Investor Blog 9Questcor Pharmaceuticals Responds to Questions From Investor Blog 10Questcor Pharmaceuticals Responds to Questions From Investor Blog 11Questcor Pharmaceuticals Responds to Questions From Investor Blog 12Questcor Pharmaceuticals Responds to Questions From Investor Blog 13Questcor Pharmaceuticals Responds to Questions From Investor Blog 14Questcor Pharmaceuticals Responds to Questions From Investor Blog 15Questcor Pharmaceuticals Responds to Questions From Investor Blog 16Questcor Pharmaceuticals Responds to Questions From Investor Blog 17
(Date:9/30/2014)... September 30, 2014 FDA-approved injectable ... Poly-L-lactic acid) are used in several procedures that ... in patients, but are primarily used for wrinkle ... rejuvenation—in particular, these fillers are being used as ... restoring smoother skin in the hands. (1) (2) ...
(Date:9/30/2014)... Healthpointe is proud to announce that Dr. ... ankle reconstruction surgeries to assist patients with severe orthopedic ... in the diagnosis and treatment of sports medicine, and ... trained to perform advanced Foot and Ankle Reconstruction to ... also fluent in Spanish. , Reconstructive surgical procedures for ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 To mark ... Editorial Board of Living with a Disability magazine ... light on hematological disorders as disabling conditions. ... more than a diagnosis to establish a disability related ... thrombocytomenia, myelofibrosis, hereditary telangiectasia, coagulation defects, polycythemia vera, and ...
(Date:9/30/2014)... 2014 Jiwa Law Corporation, a personal injury ... will now be offering free consultation for personal injury claims ... law firm for the first time to meet the Vancouver ... the opportunity to understand what their rights are. The experts ... client to explain to them what the law firm can ...
(Date:9/30/2014)... Coast Dental and Orthodontics is proud ... located at 1010 Shaw Avenue in Clovis, CA. The ... , and specialty dental care including orthodontics, endodontics, periodontics, ... convenient dental care, our Clovis dentists also strive to ... Dental at 559-777-6113 to schedule an appointment. , Our ...
Breaking Medicine News(10 mins):Health News:Nonsurgical Cosmetic How-To: Skinspirations Details Proper Use of FDA-Approved Injectable Fillers for Hand Rejuvenation Procedures 2Health News:Nonsurgical Cosmetic How-To: Skinspirations Details Proper Use of FDA-Approved Injectable Fillers for Hand Rejuvenation Procedures 3Health News:Nonsurgical Cosmetic How-To: Skinspirations Details Proper Use of FDA-Approved Injectable Fillers for Hand Rejuvenation Procedures 4Health News:Fellowship-Trained and Board-Certified Orthopedic Specialist Now Performing Advanced Foot & Ankle Reconstruction Surgeries 2Health News:Fellowship-Trained and Board-Certified Orthopedic Specialist Now Performing Advanced Foot & Ankle Reconstruction Surgeries 3Health News:Living with a Disability Magazine Marks National Sickle Cell Health Month with New Article on Hematological Disorders 2Health News:Living with a Disability Magazine Marks National Sickle Cell Health Month with New Article on Hematological Disorders 3Health News:Jiwa Law Corporation Now Offers Personal Injury Consultation Without Any Charge 2Health News:Coast Dental Clovis Celebrates Grand Opening 2Health News:Coast Dental Clovis Celebrates Grand Opening 3
... Ad For Containing,Inappropriate, Content While Original PP:GG Content ... "It is outrageous that,YouTube would black-out our video ... while it continues to carry the original Planned,Parenthood ... Life League., The "inappropriate nature" cited by ...
... Promising results need to be replicated in larger study, ... A drug originally designed to combat cancer that is ... rheumatoid arthritis and lupus might also work against a ... published in the Feb. 14 issue of the ...
... Feb. 13 DaVita Inc.,(NYSE: DVA ) today ... 2007. Net income for the three months ended December ... compared to $74.1 million, or $0.70 per,share, for the ... Net income for the year ended December 31, ...
... February 13, 2008 Eight outstanding cancer care providers ... chosen to receive the 2008 American Cancer Society Lane ... prize for cancer caring. The Lane W. Adams Quality ... difference through innovation, leadership, and consistent excellence in providing ...
... Feb. 13 NightHawk,Radiology Holdings, Inc. (Nasdaq: NHWK ), ... United States, today announced,financial results for its fourth quarter and ... -- Full year revenues grew 65% to $151.7 million from ... Organic revenue grew $21.4 million, or 23% ...
... WALTHAM, Mass., Feb. 13 Inverness Medical,Innovations, Inc. ... rapid point-of-care,diagnostic products, today announced that it will ... 20, 2008. The Company will,also host a conference ... that,date to discuss these results and other corporate ...
Cached Medicine News:Health News:ICYMI: YouTube Censors American Life League 2Health News:Cancer Drug Works Against MS in Early Trial 2Health News:Cancer Drug Works Against MS in Early Trial 3Health News:DaVita 4th Quarter 2007 Results 2Health News:DaVita 4th Quarter 2007 Results 3Health News:DaVita 4th Quarter 2007 Results 4Health News:DaVita 4th Quarter 2007 Results 5Health News:DaVita 4th Quarter 2007 Results 6Health News:DaVita 4th Quarter 2007 Results 7Health News:DaVita 4th Quarter 2007 Results 8Health News:DaVita 4th Quarter 2007 Results 9Health News:DaVita 4th Quarter 2007 Results 10Health News:DaVita 4th Quarter 2007 Results 11Health News:DaVita 4th Quarter 2007 Results 12Health News:DaVita 4th Quarter 2007 Results 13Health News:DaVita 4th Quarter 2007 Results 14Health News:DaVita 4th Quarter 2007 Results 15Health News:DaVita 4th Quarter 2007 Results 16Health News:DaVita 4th Quarter 2007 Results 17Health News:American Cancer Society honors exemplary cancer caregivers 2Health News:American Cancer Society honors exemplary cancer caregivers 3Health News:NightHawk Radiology Holdings, Inc. Announces Fourth Quarter and Full-Year 2007 Results; Updates 2008 Guidance 2Health News:NightHawk Radiology Holdings, Inc. Announces Fourth Quarter and Full-Year 2007 Results; Updates 2008 Guidance 3Health News:NightHawk Radiology Holdings, Inc. Announces Fourth Quarter and Full-Year 2007 Results; Updates 2008 Guidance 4Health News:NightHawk Radiology Holdings, Inc. Announces Fourth Quarter and Full-Year 2007 Results; Updates 2008 Guidance 5Health News:NightHawk Radiology Holdings, Inc. Announces Fourth Quarter and Full-Year 2007 Results; Updates 2008 Guidance 6Health News:NightHawk Radiology Holdings, Inc. Announces Fourth Quarter and Full-Year 2007 Results; Updates 2008 Guidance 7Health News:NightHawk Radiology Holdings, Inc. Announces Fourth Quarter and Full-Year 2007 Results; Updates 2008 Guidance 8Health News:NightHawk Radiology Holdings, Inc. Announces Fourth Quarter and Full-Year 2007 Results; Updates 2008 Guidance 9Health News:NightHawk Radiology Holdings, Inc. Announces Fourth Quarter and Full-Year 2007 Results; Updates 2008 Guidance 10Health News:NightHawk Radiology Holdings, Inc. Announces Fourth Quarter and Full-Year 2007 Results; Updates 2008 Guidance 11Health News:NightHawk Radiology Holdings, Inc. Announces Fourth Quarter and Full-Year 2007 Results; Updates 2008 Guidance 12Health News:NightHawk Radiology Holdings, Inc. Announces Fourth Quarter and Full-Year 2007 Results; Updates 2008 Guidance 13Health News:NightHawk Radiology Holdings, Inc. Announces Fourth Quarter and Full-Year 2007 Results; Updates 2008 Guidance 14Health News:NightHawk Radiology Holdings, Inc. Announces Fourth Quarter and Full-Year 2007 Results; Updates 2008 Guidance 15
The VPAP III ST is a complete system solution for SDB, providing comfortable and effective bilevel treatment with additional treatment modes. The VPAP III ST is an effective business solution for cli...
The GoodKnight® 425 Bi-Level® device is suitable for travel and includes features such as automatic altitude compensation, optional cigarette lighter adapter and portable battery pack...
... The BiPAP Pro with Bi-Flex bi-level ... time that the BiPAP Pro takes to ... includes Digital Auto-Trak Sensitivity™ which automatically triggers ... expiratory pressures based on the patients breathing ...
... Electrophoresis System (PGGE) is designed to ... density lipoproteins (LDL) and high density ... using nondenaturing pore gradient gel electrophoresis. ... short DNA sequencing runs. Temperature control ...
Medicine Products: